Literature DB >> 10147037

Principles of pharmacoeconomic analysis of drug therapy.

D A Freund1, R S Dittus.   

Abstract

Economic analyses have become increasingly important in healthcare in general and with respect to pharmaceuticals in particular. If economic analyses are to play an important and useful role in the allocation of scarce healthcare resources, then such analyses must be performed properly and with care. This article outlines some of the basic principles of pharmacoeconomic analysis. Every analysis should have an explicitly stated perspective, which, unless otherwise justified, should be a societal perspective. Cost minimisation, cost-effectiveness, cost-utility and cost-benefit analyses are a family of techniques used in economic analyses. Cost minimisation analysis is appropriate when alternative therapies have identical outcomes, but differ in costs. Cost-effectiveness analysis is appropriate when alternative therapies differ in clinical effectiveness but can be examined from the same dimension of health outcome. Cost-utility analysis can be used when alternative therapies may be examined using multiple dimensions of health outcome, such as morbidity and mortality. Cost-benefit analysis requires the benefits of therapy to be described in monetary units and is not usually the technique of choice. The technique used in an analysis should be described and explicitly defended according to the problem being examined. For each technique, the method of determining costs is the same; direct, indirect, and intangible costs can be considered. The specific costs to be used depend on the analytical perspective; a societal perspective implies the use of both direct and indirect economic costs. A modelling framework such as a decision tree, influence diagram, Markov chain, or network simulation must be used to structure the analysis explicitly. Regardless of the choice of framework, all modelling assumptions should be described. The mechanism of data collection for model inputs must be detailed and defended. Models must undergo careful verification and validation procedures. Following baseline analysis of the model, further analyses should examine the role of uncertainty in model assumptions and data.

Mesh:

Year:  1992        PMID: 10147037     DOI: 10.2165/00019053-199201010-00006

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  30 in total

Review 1.  Quality of life, health status, and clinical research.

Authors:  M Bergner
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

2.  Guidelines for the clinical and economic evaluation of health care technologies.

Authors:  G Guyatt; M Drummond; D Feeny; P Tugwell; G Stoddart; R B Haynes; K Bennett; R Labelle
Journal:  Soc Sci Med       Date:  1986       Impact factor: 4.634

3.  Health economics: an introduction for clinicians.

Authors:  M Drummond; G Stoddart; R Labelle; R Cushman
Journal:  Ann Intern Med       Date:  1987-07       Impact factor: 25.391

Review 4.  Calculating costs of drug therapy: a review of a decade of literature (1977-1987).

Authors:  C A Simpson; P F Souney
Journal:  Clin Ther       Date:  1988       Impact factor: 3.393

Review 5.  Clinical economics. A guide to the economic analysis of clinical practices.

Authors:  J M Eisenberg
Journal:  JAMA       Date:  1989-11-24       Impact factor: 56.272

6.  Quality-adjusted life years, utility theory, and healthy-years equivalents.

Authors:  A Mehrez; A Gafni
Journal:  Med Decis Making       Date:  1989 Apr-Jun       Impact factor: 2.583

7.  Clinical trials to evaluate cost-effectiveness.

Authors:  B J Hillman; J P Kahan; C R Neu; G T Hammons
Journal:  Invest Radiol       Date:  1989-02       Impact factor: 6.016

8.  Quantifying uncertainty in medical decisions.

Authors:  R S Dittus; S D Roberts; J R Wilson
Journal:  J Am Coll Cardiol       Date:  1989-09       Impact factor: 24.094

9.  Variance estimation for medical decision analysis.

Authors:  B P Katz; S L Hui
Journal:  Stat Med       Date:  1989-02       Impact factor: 2.373

10.  Economic aspects of clinical decision making: applications in patient care.

Authors:  G Oster
Journal:  Am J Hosp Pharm       Date:  1988-03
View more
  64 in total

1.  Quality assessment of economic evaluations published in PharmacoEconomics. The first four years (1992 to 1995).

Authors:  M Iskedjian; K Trakas; C A Bradley; A Addis; K Lanctôt; D Kruk; A L Ilersich; T R Einarson
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

Review 2.  The (near) equivalence of cost-effectiveness and cost-benefit analyses. Fact or fallacy?

Authors:  C Donaldson
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

Review 3.  Pharmacoeconomics of immunisation: a review.

Authors:  R van den Oever; D de Graeve; B Hepp; A Stroobant; D Walckiers; V Van Casteren; F Van Loock; G Ducoffre; J Dewatripont; P Jacques
Journal:  Pharmacoeconomics       Date:  1993-04       Impact factor: 4.981

4.  High technology drugs for cancer: the decision process for adding to a formulary.

Authors:  J L Glennie; D M Woloschuk; K W Hall
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

Review 5.  Expanding the role of pharmacists in pharmacoeconomics: why and how?

Authors:  L A Sanchez
Journal:  Pharmacoeconomics       Date:  1994-05       Impact factor: 4.981

6.  The influence of pharmacoeconomic factors on prescribing patterns in Ireland.

Authors:  J Feely
Journal:  Pharmacoeconomics       Date:  1992-08       Impact factor: 4.981

7.  Economic evaluation of drugs: a UK pharmaceutical industry perspective.

Authors:  N Wells
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

8.  The validity and reproducibility of a work productivity and activity impairment instrument.

Authors:  M C Reilly; A S Zbrozek; E M Dukes
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

9.  The cost effectiveness of drug utilisation review in an outpatient setting.

Authors:  D H Kreling; D A Mott
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

Review 10.  Economics of home intravenous services.

Authors:  N D Thickson
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.